Search

The ISARIC 4C Mortality score was developed to predict mortality risk among patients with COVID-19. Its performance among vaccinated individuals is understudied. This is a retrospective study of all patients with SARS-CoV-2 infection admitted to the National Centre for Infectious Diseases, Singapore, from January-2020 to December-2021. Demographic, clinical, and laboratory data were extracted, and multiple logistic regression (MLR) models were developed to predict the relationship between ISARIC score, vaccination status, anti-S antibody titre, and severe COVID-19. A total of 6377 patients were identified, of which 5329 met the study eligibility criteria. The median age of the patients was 47 years (IQR 35–71), 1264 (23.7%) were female, and 1239 (25.7%) were vaccinated. Severe disease occurred in 499 (9.4%) patients, including 133 (2.5%) deaths. After stratification, 3.0% of patients with low (0–4), 17.8% of patients with moderate (5–9), and 36.2% of patients with high (≥10) ISARIC scores developed severe COVID-19. Vaccination was associated with a reduced risk of progression to severe COVID-19 in the MLR model: aOR 0.88 (95% CI: 0.86–0.90), and the risk of severe COVID-19 decreased inversely to anti-S antibody titres. The anti-S antibody titre should be further investigated as an adjunct to the ISARIC score to triage COVID-19 patients for hospital admission and antiviral therapy.

Chest X-rays (CXRs) are essential in the preliminary radiographic assessment of patients affected by COVID-19. Junior residents, as the first point-of-contact in the diagnostic process, are expected to interpret these CXRs accurately. We aimed to assess the effectiveness of a deep neural network in distinguishing COVID-19 from other types of pneumonia, and to determine its potential contribution to improving the diagnostic precision of less experienced residents. A total of 5051 CXRs were utilized to develop and assess an artificial intelligence (AI) model capable of performing three-class classification, namely non-pneumonia, non-COVID-19 pneumonia, and COVID-19 pneumonia. Additionally, an external dataset comprising 500 distinct CXRs was examined by three junior residents with differing levels of training. The CXRs were evaluated both with and without AI assistance. The AI model demonstrated impressive performance, with an Area under the ROC Curve (AUC) of 0.9518 on the internal test set and 0.8594 on the external test set, which improves the AUC score of the current state-of-the-art algorithms by 1.25% and 4.26%, respectively. When assisted by the AI model, the performance of the junior residents improved in a manner that was inversely proportional to their level of training. Among the three junior residents, two showed significant improvement with the assistance of AI. This research highlights the novel development of an AI model for three-class CXR classification and its potential to augment junior residents’ diagnostic accuracy, with validation on external data to demonstrate real-world applicability. In practical use, the AI model effectively supported junior residents in interpreting CXRs, boosting their confidence in diagnosis. While the AI model improved junior residents’ performance, a decline in performance was observed on the external test compared to the internal test set. This suggests a domain shift between the patient dataset and the external dataset, highlighting the need for future research on test-time training domain adaptation to address this issue.

Advances in our understanding of the role of magnetic resonance imaging (MRI) for the detection of prostate cancer have enabled its integration into clinical routines in the past two decades. The Prostate Imaging Reporting and Data System (PI-RADS) is an established imaging-based scoring system that scores the probability of clinically significant prostate cancer on MRI to guide management. Image fusion technology allows one to combine the superior soft tissue contrast resolution of MRI, with real-time anatomical depiction using ultrasound or computed tomography. This allows the accurate mapping of prostate cancer for targeted biopsy and treatment. Machine learning provides vast opportunities for automated organ and lesion depiction that could increase the reproducibility of PI-RADS categorisation, and improve co-registration across imaging modalities to enhance diagnostic and treatment methods that can then be individualised based on clinical risk of malignancy. In this article, we provide a comprehensive and contemporary review of advancements, and share insights into new opportunities in this field.